Regulation of immune microenvironment may enable MET-altered NSCLC patients to benefit from immune checkpoint inhibitors

Targeted therapies have remained standard treatment for patients with driving alterations. After exhaustion of targeted therapy and chemotherapy, immunotherapies have been the ultimate resort for these patients [1,2]. However, the role of immunotherapy remains a controversial issue for patients with oncogenic driver gene mutations. For instance, EGFR-mutated lung adenocarcinoma (LUAD) patients were reported to be resistant to immunotherapy [3]. Patients with KRAS-mutant or BRAF-mutant NSCLC derived an increased benefit from immunotherapy than EGFR-mutant NSCLC [4,5].

Source: Lung Cancer - February 17, 2021 Category: Cancer & Oncology Authors: Chenyue Zhang, Haiyong Wang Source Type: research